Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for stage I-III HER2-positive breast cancer: Results of a single-arm pilot clinical trial

被引：0
|
作者：
Jiang, Jun [1 ]
机构：
[1] Army Med Univ, Chongqing, Peoples R China
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS11-24
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Neoadjuvant pyrotinib plus trastuzumab, and chemoterapy in patients with HER2-positive early breast cancer: a real-world study
    Zhou, Jun
    Wang, Rui
    CANCER RESEARCH, 2024, 84 (09)
  • [22] Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer
    Julia Foldi
    Sarah Mougalian
    Andrea Silber
    Donald Lannin
    Brigid Killelea
    Anees Chagpar
    Nina Horowitz
    Courtney Frederick
    Lawrence Rispoli
    Trisha Burrello
    Maysa Abu-Khalaf
    Kert Sabbath
    Tara Sanft
    Debra S. Brandt
    Erin W. Hofstatter
    Christos Hatzis
    Michael P. DiGiovanna
    Lajos Pusztai
    Breast Cancer Research and Treatment, 2018, 169 : 333 - 340
  • [23] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1673 - 1684
  • [24] Complete response after "neoadjuvant" pertuzumab plus trastuzumab plus docetaxel chemotherapy in Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 836 - 837
  • [25] Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial
    Zhong, Xiaorong
    He, Ping
    Chen, Jie
    Yan, Xi
    Wei, Bin
    Zhang, Zhang
    Bu, Hong
    Li, Jing
    Tian, Tinglun
    Lv, Qing
    Wang, Xiaodong
    Li, Hongjiang
    Wang, Jing
    Huang, Juan
    Suo, Jiaojiao
    Liu, Xiaoxiao
    Zheng, Hong
    Luo, Ting
    GLAND SURGERY, 2022, 11 (01) : 216 - +
  • [26] Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
    Loi, Sherene
    Giobbie-Hurder, Anita
    Gombos, Andrea
    Bachelot, Thomas
    Hui, Rina
    Curigliano, Giuseppe
    Campone, Mario
    Biganzoli, Laura
    Bonnefoi, Herve
    Jerusalem, Guy
    Bartsch, Rupert
    Rabaglio-Poretti, Manuela
    Kammler, Roswitha
    Maibach, Rudolf
    Smyth, Mark J.
    Di Leo, Angelo
    Colleoni, Marco
    Viale, Giuseppe
    Regan, Meredith M.
    Andre, Fabrice
    Fumagalli, Debora
    Gelber, Richard D.
    Goulioti, Theodora
    Hiltbrunner, Anita
    Hui, Rita
    Roschitzki, Heidi
    Ruepp, Barbara
    Boyle, Fran
    Stahel, Rolf
    Aebi, Stefan
    Coates, Alan S.
    Goldhirsch, Aron
    Karlsson, Per
    Kossler, Ingrid
    Fournarakou, Stamatina
    Gasca, Adriana
    Pfister, Rita
    Ribeli-Hofmann, Sabrina
    Weber, Magdelena
    Celotto, Daniela
    Comune, Carmen
    Frapolli, Michela
    Sanchez-Hohl, Magdalena
    Huang, Hui
    Mahoney, Caitlin
    Price, Karen
    Scott, Karolyn
    Shaw, Holly
    Fischer, Susan
    Greco, Monica
    LANCET ONCOLOGY, 2019, 20 (03): : 371 - 382
  • [27] Inetetamab combined with pyrotinib and Chemotherapy in Pretreated Patients with HER2-positive metastatic breast cancer, a single arm, multicenter phase II clinical trial
    Zhao, Jianli
    Cai, Yangyang
    Ding, Linxiaoxiao
    Yang, Yaping
    Zou, Guorong
    Yao, Herui
    Wang, Ying
    CANCER RESEARCH, 2023, 83 (05)
  • [28] Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial
    Zhao, Jianli
    Yu, Yunfang
    Ren, Wei
    Ding, Linxiaoxiao
    Chen, Yongjian
    Yuan, Peng
    Yue, Jian
    Yang, Yaping
    Zou, Guorong
    Chen, Tao
    Chai, Jie
    Zhang, Li
    Wu, Wenjing
    Zeng, Yinduo
    Gui, Xiujuan
    Cai, Yangyang
    Luo, Simin
    Yuan, Zhongyu
    Zhang, Kang
    Yao, Herui
    Wang, Ying
    MEDCOMM, 2025, 6 (01):
  • [29] Comparison of the prognostic effect of pyrotinib plus trastuzumab and chemotherapy different lines therapy in HER2-positive advanced breast cancer
    Zhou, Yangqingqing
    Wang, Hui
    Yang, Jiao
    Wang, Fan
    Dong, Danfeng
    Zhao, Xiaoai
    Wang, Le
    He, Ruiyuan
    Ruan, Zhiping
    Yang, Jin
    JOURNAL OF CHEMOTHERAPY, 2025, 37 (02) : 135 - 145
  • [30] Neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer: A pilot trial.
    Xue, Jinqi
    Niu, Nan
    Wang, Shuo
    Chen, Guanglei
    Qiu, Fang
    Zhao, Yi
    Xing, Fei
    Zheng, Xinyu
    Tu, Wei
    Li, Ke
    Zhao, Hai
    Tang, Meiyue
    Xu, Qianshi
    Liu, Chao
    Zhao, Yafei
    Jiang, Xiaofan
    Huo, Shiwen
    Pang, Zheng
    Zhang, Dianlong
    Liu, Caigang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345